High-Dose Chemotherapy plus Autologous Bone Marrow Transplantation for Metastatic Breast Cancer
- 13 April 2000
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 342 (15) , 1119-1120
- https://doi.org/10.1056/nejm200004133421508
Abstract
In this issue of the Journal, Stadtmauer et al. present the results of a clinical trial in which conventional-dose chemotherapy was compared with high-dose chemotherapy plus autologous bone marrow transplantation (hematopoietic stem-cell rescue) in patients with metastatic breast cancer.1 In this trial, 553 women with previously untreated metastatic or locally recurrent breast cancer were initially treated with conventional multidrug chemotherapy; patients who had a response, according to predefined objective criteria, were then randomly assigned to receive either maintenance chemotherapy at standard doses or high-dose chemotherapy plus an autologous bone marrow transplant. In this randomization phase, a total of 199 women . . .Keywords
This publication has 4 references indexed in Scilit:
- Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast CancerNew England Journal of Medicine, 2000
- Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.Journal of Clinical Oncology, 1997
- Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer.Journal of Clinical Oncology, 1997
- Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.Journal of Clinical Oncology, 1997